Silexion Therapeutics Faces Nasdaq Listing Challenge Amid Bid Price Deficiency Warning

Reuters
07/22
Silexion <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Faces Nasdaq Listing Challenge Amid Bid Price Deficiency Warning

Silexion Therapeutics Corp. has received a notice from the Nasdaq Stock Market LLC regarding a regulatory issue related to its stock listing. The Listing Qualifications Department informed Silexion that the closing bid price of its ordinary shares has been below the minimum $1.00 per share requirement for 30 consecutive business days, as per Nasdaq Listing Rule 5550(a)(2). This bid price deficiency could impact Silexion's continued listing on the Nasdaq Capital Market. While the letter does not immediately affect the trading of Silexion's ordinary shares or warrants, it will be considered by the Nasdaq hearings panel in deciding whether the company can remain listed. Silexion has until September 19, 2025, to meet compliance terms and achieve the required standards for listing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-002431), on July 21, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10